Compare JRSH & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JRSH | BOLD |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 60.8M |
| IPO Year | 2017 | 2024 |
| Metric | JRSH | BOLD |
|---|---|---|
| Price | $5.82 | $2.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.00 | $4.00 |
| AVG Volume (30 Days) | 79.8K | ★ 120.7K |
| Earning Date | 02-09-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.68% | N/A |
| EPS Growth | ★ 485.71 | 32.47 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $166,263,870.00 | N/A |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $10.06 | N/A |
| P/E Ratio | $45.38 | ★ N/A |
| Revenue Growth | ★ 14.03 | N/A |
| 52 Week Low | $2.85 | $0.96 |
| 52 Week High | $5.97 | $3.16 |
| Indicator | JRSH | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 60.95 | 34.56 |
| Support Level | $3.01 | $2.39 |
| Resistance Level | $5.81 | $2.64 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 83.50 | 4.57 |
Jerash Holdings (US) Inc along with its subsidiaries, is a manufacturer and exporter of customized, ready-made sport and outerwear from knitted fabric from its production facilities in Jordan. The company manufactures for retailers, including Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation, and Philip-Van Heusen, which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, Calvin Klein, Tommy Hilfiger, IZOD, and Speedo. It derives its revenue from the manufacturing and sales of outerwear in the United States. The company's product offering consists of jackets, polo shirts, crew neck shirts, pants, and shorts made from knitted fabric. Geographically, the company generates maximum revenue from the United States.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.